Active, not recruiting
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
NCT05312411
- Conditions
- Bone Diseases, Bone Neoplasms, Musculoskeletal Diseases, +8 more
- Locations
-
- Seattle Children's Hospital Seattle, Washington, United States